tweetindex
TH

Tom Powles ✓

@tompowles1 · joined 16 Dec 2019

Interested in Urology Cancers, biomarkers and drug development.

13 951Followers
88Following
2 562Posts total
84.4KViews on collected posts

โพสต์ล่าสุด

How do we sequence ADCs after EVP in advanced bladder cancer. @DrRosenbergMSK Switching payload appears more important than switching target. iZABREN (HER1/3 Topo1) vs platinum chemo and SACTMT (TROP2/TOPO1 vs taxane) in EVP resistant disease are enrolling #GuardSymposium2026 htt
859 views · 10 likes · 8 reposts · 0 replies Open on X →
Will there be local relapses when we pursue surgery sparing approaches with EVP and without radiotherapy in muscle invasive bladder cancer (EV209/EV309) @AndreaNecchi . Can we reduce this risk with local therapy (TAR200 BCG etc) #GuardSymposium2026 https://t.co/RzVIAKWau2
434 views · 11 likes · 5 reposts · 0 replies Open on X →
While PD-L1 has been inconsistent as a biomarker in UC, T cell effector signatures have correlated with response to ICI therapy #Guardsymposium26. The data presented by @scocmem shows this signature is associated with poor rather than good outcomes with BCG. This initially https:
903 views · 19 likes · 12 reposts · 0 replies Open on X →
After the positive press release for the Moderna personalised cancer vaccine (adjuvant therapy in combo with pembro in melanoma) we get a negative press release (‘imbalances in OS’ ➡️early termination) for the BioNTech PCV (monotherapy, sequenced after chemo, in ctDNA+ve adjuvant
43.4K views · 100 likes · 31 reposts · 14 replies Open on X →
Personalized mRNA-based neoantigen vaccines + pembo are being tested in a number of randomised adjuvant cancer trials (included bladder and renal). The 1st positive trial (RIII in melanoma) was announced today. PCVs are logistically complex with limited monotherapy activity in h
21.2K views · 157 likes · 39 reposts · 7 replies Open on X →
@tompowles1 @DrChoueiri Congrats @DrChoueiri very well deserved! 154 views · 3 likes · 0 reposts · 0 replies Open on X →
@tompowles1 @DrChoueiri A real Giant in Oncology!!! 335 views · 3 likes · 1 reposts · 0 replies Open on X →
@tompowles1 @DrChoueiri Wow Toni! 👏👏👏 132 views · 3 likes · 1 reposts · 0 replies Open on X →
Toni Choueiri @DrChoueiri receiving the lifetime achievement award #KCRS26 . Leading a plethora of practice changing trials from METEOR to LITESPARK. >900 publications. Amazing achievement and well deserved. https://t.co/rMlAc2lZng
17K views · 198 likes · 31 reposts · 14 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

5 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม แสดงไปไกลเกินผู้ติดตามของตัวเอง และผู้ชมก็ตอบสนอง.

ยอดดูมัธยฐาน903บัญชีนี้924ค่ามัธยฐานของ 10K–100K
การเข้าถึง, %6.47%บัญชีนี้3.62%ค่ามัธยฐานของ 10K–100K
การมีส่วนร่วม, %2.21%บัญชีนี้1.52%ค่ามัธยฐานของ 10K–100K
ตัวชี้วัดบัญชีนี้ค่ามัธยฐานของ 10K–100Kอัตราส่วน
ยอดดูมัธยฐานต่อโพสต์9039240.98×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)6.47%3.62%1.79×
อัตราการมีส่วนร่วม2.21%1.52%1.45×

บัญชีอื่นในช่วงนี้ →   เปรียบเทียบกับบัญชีอื่น →   ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

17K23 Jul
13224 Jul
335
154
21.2K19 Aug
43.4K29 Aug
90318 Sep
434
859

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.47%23 Jul
3.03%24 Jul
1.19%
1.95%
0.98%19 Aug
0.34%29 Aug
3.43%18 Sep
3.69%
2.21%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes70.1%504 in total
Reposts17.8%128 in total
Replies4.9%35 in total
Quotes2.1%15 in total
Bookmarks5.1%37 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

บัญชีที่คล้ายกัน